R

Retina Foundation of the Southwest | Dallas, TX

Research site
(Unclaimed)
Location
9600 North Central Expressway Suite 200, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

QR-421a
VP-001
Zimura
GT005
Dorzolamide
Brimonidine
QLT091001
brinzolamide
BI 754132
AVD-104

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 61 total trials

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: 4D-125 IVT Injection
Other: Observational

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to a...

Enrolling
X-Linked Retinitis Pigmentosa
Drug: Control
Biological: rAAV2tYF-GRK1-hRPGRco
Locations recently updated

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a...

Invitation-only
X-Linked Retinitis Pigmentosa
Biological: AGTC-501 (high dose and standard corticosteroid regimen)
Biological: AGTC-501 (low dose and standard corticosteroid regimen)

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retini...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: rAAV2tYF-GRK1-RPGR

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in sub...

Active, not recruiting
Eye Diseases, Hereditary
Vision Tunnel
Drug: QR-1123
Other: Sham procedure

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated vi...

Active, not recruiting
Choroideremia
Biological: 4D-110

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subj...

Active, not recruiting
Dry Age-related Macular Degeneration
Drug: GT005: Medium Dose
Drug: GT005: High Dose

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants wit...

Not yet enrolling
Retinal Degeneration
Retinal Dystrophies
Drug: VP-001

Currently enrolling a total of 12 patients for Phase 2a of the study: 6 patients must have VA of no-better-than hand motion in the study eye, and 6 p...

Active, not recruiting
Advanced Retinitis Pigmentosa
Drug: RST-001

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants...

Enrolling
PRPF31 Mutationassociated Retinal Dystrophy
Retinal Dystrophy
Drug: VP-001

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retini...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: rAAV2tYF-GRK1-RPGR

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD)....

Enrolling
Geographic Atrophy
Genetic: OCU410

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.This is a multicenter study, which will be conducted in...

Enrolling
Stargardt Disease
Genetic: OCU410ST

The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects...

Active, not recruiting
Eye Diseases, Hereditary
Eye Disorders Congenital
Other: Sham-procedure
Drug: Ultevursen

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with a...

Active, not recruiting
Stargardt's Macular Dystrophy
Drug: Sham
Drug: avacincaptad pegol

Trial sponsors

P
R
B
4
A
Genentech logo
Jaeb Center for Health Research logo
P
S
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems